S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
China fines former NBA star Lin over quarantine comments
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
The 3-Stock Retirement Blueprint (Ad)
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
China fines former NBA star Lin over quarantine comments
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
The 3-Stock Retirement Blueprint (Ad)
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
China fines former NBA star Lin over quarantine comments
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
The 3-Stock Retirement Blueprint (Ad)
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Improve Mental Health Next Year by Breaking 17 Financial Rules
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
China fines former NBA star Lin over quarantine comments
Can ZIM Defy Broad Downturn In The Container Shipping Industry?
The 3-Stock Retirement Blueprint (Ad)
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Okta Inc Celebrates Earnings Beat But Can They Sustain the Boost?
NASDAQ:ALKS

Alkermes - ALKS Stock Forecast, Price & News

$26.09
+0.89 (+3.53%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$24.85
$26.17
50-Day Range
$21.94
$26.09
52-Week Range
$21.75
$32.79
Volume
1.98 million shs
Average Volume
1.54 million shs
Market Capitalization
$4.29 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.89

Alkermes MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
14.6% Upside
$29.89 Price Target
Short Interest
Bearish
5.54% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.17
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.32) to ($0.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

Medical Sector

899th out of 1,052 stocks

Pharmaceutical Preparations Industry

438th out of 514 stocks

ALKS stock logo

About Alkermes (NASDAQ:ALKS) Stock

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

ALKS Stock News Headlines

Brokerages Set Alkermes plc (NASDAQ:ALKS) PT at $29.67
Alkermes (NASDAQ:ALKS) PT Raised to $36.00
The Four Major Dimensions of Recovery - Yahoo Finance
See More Headlines
Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

ALKS Company Calendar

Last Earnings
11/02/2022
Today
12/03/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/15/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALKS
CUSIP
G0176710
Employees
2,211
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$29.89
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+14.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-48,170,000.00
Pretax Margin
-12.85%

Debt

Sales & Book Value

Annual Sales
$1.17 billion
Cash Flow
$0.78 per share
Book Value
$6.35 per share

Miscellaneous

Free Float
156,491,000
Market Cap
$4.29 billion
Optionable
Optionable
Beta
0.61

Social Links


Key Executives

  • Mr. Richard F. PopsMr. Richard F. Pops (Age 60)
    Chairman & CEO
    Comp: $2.28M
  • Mr. Iain Michael BrownMr. Iain Michael Brown (Age 53)
    Sr. VP & CFO
    Comp: $802k
  • Mr. Blair C. Jackson (Age 49)
    Exec. VP & COO
    Comp: $927.1k
  • Mr. David Joseph GaffinMr. David Joseph Gaffin (Age 50)
    Exec. VP, Chief Legal Officer, Chief Compliance Officer & Sec.
    Comp: $937.84k
  • Dr. Craig C. Hopkinson M.D.Dr. Craig C. Hopkinson M.D. (Age 54)
    Exec. VP of R&D and Chief Medical Officer
    Comp: $1.13M
  • Dr. Floyd E. Bloom M.D. (Age 85)
    Founder
  • Mr. Thomas Harvey
    Chief Information Officer & Sr. VP of IT
  • Ms. Sandra Coombs
    Sr. VP of Corp. Affairs & Investor Relations
  • Mr. Michael J. LandineMr. Michael J. Landine (Age 68)
    Sr. VP of Corp. Devel. & Chief Risk Officer
  • Mr. Stephen Schiavo
    Sr. VP of HR













ALKS Stock - Frequently Asked Questions

Should I buy or sell Alkermes stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALKS shares.
View ALKS analyst ratings
or view top-rated stocks.

What is Alkermes' stock price forecast for 2023?

7 analysts have issued 12 month price targets for Alkermes' stock. Their ALKS share price forecasts range from $25.00 to $36.00. On average, they anticipate the company's share price to reach $29.89 in the next year. This suggests a possible upside of 14.6% from the stock's current price.
View analysts price targets for ALKS
or view top-rated stocks among Wall Street analysts.

How have ALKS shares performed in 2022?

Alkermes' stock was trading at $23.26 on January 1st, 2022. Since then, ALKS stock has increased by 12.2% and is now trading at $26.09.
View the best growth stocks for 2022 here
.

When is Alkermes' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023.
View our ALKS earnings forecast
.

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) issued its quarterly earnings results on Wednesday, November, 2nd. The company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by $0.01. The company earned $252.36 million during the quarter, compared to analyst estimates of $271.45 million. Alkermes had a negative net margin of 11.41% and a negative trailing twelve-month return on equity of 1.10%. The firm's revenue was down 14.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.02) EPS.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of $0.15-$0.33 for the period, compared to the consensus earnings per share estimate of $0.20. The company issued revenue guidance of $1.07 billion-$1.12 billion, compared to the consensus revenue estimate of $1.10 billion.

What is Richard F. Pops' approval rating as Alkermes' CEO?

119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Who are Alkermes' major shareholders?

Alkermes' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.02%), BlackRock Inc. (9.43%), State Street Corp (3.94%), Hardman Johnston Global Advisors LLC (3.49%), Renaissance Technologies LLC (3.38%) and Primecap Management Co. CA (3.25%). Insiders that own company stock include Blair Curtis Jackson, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon.
View institutional ownership trends
.

How do I buy shares of Alkermes?

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $26.09.

How much money does Alkermes make?

Alkermes (NASDAQ:ALKS) has a market capitalization of $4.29 billion and generates $1.17 billion in revenue each year. The company earns $-48,170,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

How many employees does Alkermes have?

The company employs 2,211 workers across the globe.

Does Alkermes have any subsidiaries?
The following companies are subsidiares of Alkermes: Rodin Therapeutics.
Read More
How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The official website for the company is www.alkermes.com. The company can be reached via phone at (531) 772-8000, via email at investor_relations@alkermes.com, or via fax at 781-890-0524.

This page (NASDAQ:ALKS) was last updated on 12/3/2022 by MarketBeat.com Staff